Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.

NCT Number	NCT06774079
Lead Sponsor	University of Miami
Conditions	Crohn Disease
Enrollment	24 participants
Start Date	2025-03-05
Primary Completion	2027-03-05 (estimated)
Study Completion	2027-03-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-30